Halozyme Therapeutics Statistics
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
111.03+1.19 (+1.08%)
Market open · Delayed 15 min · as of Oct 9, 3:35 PM ET
Halozyme Therapeutics by the numbers
Halozyme Therapeutics has a market capitalization of $12.60 billion based on 113.50M shares outstanding. Its trailing P/E ratio is 32.5, below the 5-company peer median of 41.5, and its forward P/E is 10.4. The stock trades 5.6% above its 50-day average and 40.2% above its 200-day average.
Average daily trading volume is 2.18M shares, or about $242.1 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
HALO valuation vs. peer median
| Metric | HALO | Peer median | Difference |
|---|---|---|---|
| Market cap | $12.60B | $11.10B | +13% |
| P/E (TTM) | 32.5 | 41.5 | -22% |
| Forward P/E | 10.4 | 31.4 | -67% |
| Avg. volume | 2.18M | 1.87M | +17% |
Peer median across 8 companies: TECH, IBRX, RGEN, PCVX, TWST, NBIX, EXEL, KRYS.
Valuation
- Market cap
- $12.60B
- P/E (TTM)
- 32.46
- Forward P/E
- 10.44
- Price / sales (latest FY)
- 9.02
- EPS (TTM)
- $3.42
- Shares outstanding
- 113.50M
Price and trading
- Previous close
- 109.84
- Open
- 109.70
- Day range
- 109.70 – 112.65
- 52-week range
- 61.23 – 116.85
- 52-week change
- +68.47%
- 50-day moving average
- 105.10
- Beta
- —
- Volume
- 1.22M
- Average volume
- 2.18M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 2, 2026
Additional statistics
- Market Cap
- 12.60B
- Pe
- 32.46
- Forward Pe
- 10.44
- Eps
- 3.42
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 116.85
- Week52 Low
- 61.23
- Avg Volume
- 2.18M
- Shares Outstanding
- 113.50M
- Ma50
- 105.10
- Ma200
- 79.21
- Earnings Date
- Nov 2, 2026
- Pct From52w High
- -4.98%
- Pct From52w Low
- 81.33%